List Title | APhA DrugInfoLine

Endocrinology

SORT BY: Most Recent Most Viewed

March 1, 2001

Alendronate Now Approved for Weekly Dosing

READ

PREVIEW
Based on the pharmacokinetics of alendronate (Fosamax—Merck) and the physiology of the bone-remodeling process, once-weekly administration of this bisphosphonate is just as effective as...
December 1, 2000

Regimens Can Differ for Mifepristone, Misoprostol in Medical Abortion

READ

PREVIEW
Mifepristone (Mifeprex—Danco Laboratories) was approved in late September by FDA for use in a carefully described, physician-administered, three-visit plan. But according to a recently...
September 1, 2000

Transdermal Testosterone Treatment: Tolerated in Women with Premature Ovarian Failure

READ

PREVIEW
Transdermal testosterone patches have produced increased androgen levels and have been tolerated well in women with premature ovarian failure (POF). These women have lower serum androgen levels...
March 1, 2000

Postmenopausal Women: Progestin Adds to Breast Cancer Risk of HRT

READ

PREVIEW
Use of regimens combining estrogens and progestins increases the risk of breast cancer in postmenopausal women beyond the level produced by estrogens alone. Particularly in women without an...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.